IP Library Granted Patent US 7,332,185
Granted Patent B2
US 7,332,185 · App. 10/280,198 · Granted Feb 19, 2008

Complex mixtures exhibiting selective inhibition of cyclooxygenase-2

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,332,185
App. No.
10/280,198
Granted
Feb 19, 2008
Kind
B2
Abstract

A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammation response in animals. The formulation comprises comprising an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.

Claims (10)

1. A method of treating arthritis in an animal comprising administering to the animal in need thereof an effective amount of a pharmaceutical grade tetrahydroisohumulone, and an effective amount of at least one component selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, wherein said pharmaceutical grade extract provides about 0.01 to 100 mg per kg of body weight per day of tetrahydroisohumulone.

2. The method of claim 1 , wherein said step of administering provides about 0.01 to 100 mg per kg body weight per day of essential oils.

3. The method of claim 1 , wherein said animal is selected from the group consisting of humans, non-human primates, dogs, cats, birds, horses, reptiles, fish, amphibians and ruminants.

4. The method of claim 1 , wherein said step of administering is selected from the group consisting of oral, parenteral, topical, transdermal and transmucosal delivery.

5. The method of claim 1 , wherein the administering step is performed topically.

6. The method of claim 1 , further comprising a pharmaceutical acceptable carrier wherein said carrier is selected from the group consisting of coatings, isotonic and absorption delaying agents, binders, adhesives, lubricants, disintegrants, coloring agents, flavoring agents, sweetening agents, absorbants, detergents, and emulsifying agents.

7. The method of claim 1 , further comprising administering one or more members selected from the group consisting of antioxidants, vitamins and minerals.

8. The method of claim 1 , further comprising administering one or more members selected from the group consisting of proteins, fats, carbohydrates, glucosamine, chondrotin sulfate, and amino sugars.

9. The method of claim 1 , wherein the animal has osteoarthritis.

10. The method of claim 1 , wherein the animal has rheumatoid arthritis.

Assignments (7)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 057981/0156 Recorded Dec 24, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074057/0392 →
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT - REEL/FRAME 058015/0602 Recorded Dec 23, 2025
From: FORTRESS CREDIT CORP.
To: METAGENICS LLC (FKA METAGENICS, INC.); METAPROTEOMICS, LLC
Reel/Frame 074050/0670 →
SECURITY INTEREST Recorded Nov 4, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP. (AS COLLATERAL AGENT)
Reel/Frame 058015/0602 →
SECURITY INTEREST Recorded Nov 1, 2021
From: METAGENICS, INC.; METAPROTEOMICS, LLC
To: FORTRESS CREDIT CORP., AS COLLATERAL AGENT
Reel/Frame 057981/0156 →
RELEASE OF SECURITY INTEREST Recorded Oct 25, 2021
From: BANK OF AMERICA, N.A.
To: META PROTEOMICS, LLC
Reel/Frame 057909/0199 →
RELEASE OF SECURITY INTEREST Recorded Oct 26, 2009
From: COMERICA BANK
To: METAGENICS, INC.; METAGENICS FAR EAST, INC.; META PROTEOMICS, LLC
Reel/Frame 023419/0486 →
SECURITY AGREEMENT Recorded Oct 15, 2009
From: META PROTEOMICS, LLC
To: BANK OF AMERICA, N.A.
Reel/Frame 023373/0684 →